title: [Antibacterial activity and pharmacological features of fluoroquinolones and considerations on their use in a nosocomial setting].
abstract: The need for appropriate use of antimicrobials limiting the insurgence, selection and spread of bacterial resistance and preventing its diffusion to the community is increasingly widely felt. Based on some CDC expert recommendations, an antibiotic therapy should be driven by the following criteria: scientifically proven clinical evidence, high probability of being beneficial to patients, safety and tolerability, drug and regimen choice made according to the infection to be treated, and cost/efficacy ratio. In this article, we compare the microbiological and pharmacological characteristics of the three most frequently used fluoroquinolones in Italy - ciprofloxacin, levofloxacin, and moxifloxacin - highlighting the main differences and peculiar aspects for each of them. We describe the microbiological profile, providing details on bacterial resistance mechanisms, the pharmacological profile, giving details on tolerability, and the clinical profile, showing the individual therapeutic efficacy, underlining the main differences in their pharmacodynamic and pharmacokinetic aspects. The main national and international guidelines recommend ciprofloxacin and levofloxacin and, to a lesser extent, moxifloxacin, for treating nosocomial infections localised in different organs and apparatuses, including severe infections in critical patients. In addition, they represent a basic therapeutic option for treatment of community-acquired infections, such as urinary and respiratory tract infections.
authors.affiliation: Dipartimento di Patologia, Universita degli Studi di Verona, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Cornaglia
authors.forename: Raffaella
authors.initials: R
authors.lastname: Concan
authors.forename: Silvis
authors.initials: S
authors.lastname: Arrigucci
authors.forename: Andrea
authors.initials: A
authors.lastname: Novelli
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D003428:Cross Infection / Q000188:drug therapy*; D016527:Drug Costs; D004347:Drug Interactions; D024881:Drug Resistance, Bacterial; D004363:Drug Utilization; D024841:Fluoroquinolones / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones